• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidinecarboxylic acids and derivatives

5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)- (CAS No. 149771-25-5): A Comprehensive Overview

5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)-, identified by its Chemical Abstracts Service (CAS) number CAS No. 149771-25-5, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic organic molecule, featuring a pyrimidine core with substituents that include a phenyl group at the 2-position and a trifluoromethyl group at the 4-position, has garnered attention due to its potential applications in drug development and therapeutic interventions.

The structural attributes of 5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)- make it a versatile scaffold for medicinal chemists. The presence of the pyrimidine ring, a common motif in biologically active molecules, combined with the electron-withdrawing nature of the trifluoromethyl group, enhances its interaction with biological targets. This compound exhibits a balance of lipophilicity and polarity, which is crucial for optimizing pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME).

In recent years, there has been a surge in research focusing on pyrimidine derivatives due to their broad spectrum of biological activities. The< strong>2-phenyl substituent at the 2-position of the pyrimidine ring contributes to the compound's ability to engage with various enzymes and receptors. This feature has been exploited in the development of inhibitors targeting diseases such as cancer, inflammation, and infectious disorders.

One of the most compelling aspects of 5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)- is its potential as a lead compound for drug discovery. Researchers have leveraged its structure to design novel molecules with enhanced efficacy and reduced toxicity. For instance, studies have demonstrated that modifications around the pyrimidine core can modulate binding affinity to specific biological targets. This flexibility has led to the identification of several promising candidates that are currently undergoing preclinical evaluation.

The trifluoromethyl group (-CF?) is a well-documented pharmacophore that imparts unique properties to organic molecules. It enhances metabolic stability by preventing oxidative degradation and increases binding affinity through steric and electronic effects. In the context of 5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)-, this moiety plays a critical role in optimizing pharmacological activity. Recent computational studies have highlighted how the trifluoromethyl group can fine-tune the compound's interactions with biological targets, making it an attractive candidate for further development.

Advances in synthetic chemistry have enabled more efficient and scalable production methods for compounds like 5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)-. Modern techniques such as transition metal-catalyzed cross-coupling reactions have streamlined the synthesis of complex heterocyclic structures. These innovations have not only reduced production costs but also facilitated access to larger libraries of derivatives for high-throughput screening (HTS). This has accelerated the discovery process and led to the identification of several novel therapeutic agents.

The biological activity of 5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)- has been extensively studied in various disease models. Preliminary data suggest that it exhibits inhibitory effects on key enzymes involved in cancer progression. Specifically, it has shown promise in disrupting signaling pathways that are aberrantly activated in tumor cells. These findings align with broader trends in oncology research, where targeting multiple pathways simultaneously is emerging as a viable strategy for improving treatment outcomes.

In addition to its potential in oncology, this compound has also been explored for its anti-inflammatory properties. Chronic inflammation is a hallmark of numerous diseases, including cardiovascular disorders and autoimmune conditions. Studies have indicated that< strong>5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)- can modulate inflammatory responses by inhibiting key mediators such as cyclooxygenase (COX) and lipoxygenase (LOX). This dual functionality makes it an intriguing candidate for developing multi-targeted therapeutics.

The impact of computational methods on drug discovery cannot be overstated. Molecular modeling and virtual screening have become indispensable tools for identifying promising candidates like 5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)-. By leveraging these technologies, researchers can predict binding affinities and optimize molecular structures before conducting expensive wet-lab experiments. This approach has significantly reduced the time and resources required for drug development while improving success rates.

The future prospects for CAS No. 149771-25-5 are promising given its unique structural features and demonstrated biological activities. Ongoing research aims to further refine its pharmacological profile through structural modifications and analog design. Collaborative efforts between academic institutions and pharmaceutical companies are essential for translating these findings into clinical applications. As our understanding of disease mechanisms continues to evolve, compounds like this will play an increasingly important role in developing next-generation therapeutics.

In conclusion,< strong>5-Pyrimidinecarboxylic acid, 2-phenyl-4-(trifluoromethyl)-, with its CAS number CAS No. 149771-25-5, represents a significant advancement in pharmaceutical chemistry. Its structural versatility and demonstrated biological activities make it a valuable tool for drug discovery and development. With continued research and innovation, this compound holds great promise for addressing unmet medical needs across various therapeutic areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)